On June 9, BeiGene fell 3.13% in regular trading, trading at 158.0 HKD/share, with trading volume of 2.86 billion HKD. The stock continues to face downward pressure from a combination of significant shareholder reductions and prolonged sector weakness.

On the news front, Baker Bros. Advisors LP, a fund affiliated with board-level stakeholders, recently reduced its position by approximately USD 190 million. While the fund retains its board seat and holds approximately 8.21% of shares, the scale of the reduction has weighed heavily on market sentiment. Additionally, multiple directors have recently made small share disposals, further intensifying selling pressure expectations.

The broader Hong Kong-listed innovative drug sector has been in a correction for over eight months since last September, with the sector benchmark index declining more than 30% over that period. Within the Biotechnology sector today, AKESO fell 3.69% and INNOVENT BIO fell 2.12%, while BeiGene as a heavyweight leader continued to be dragged lower by overall sector weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)